Skip to main content
Intensive Care Medicine Experimental
Fig. 4 | Intensive Care Medicine Experimental

Fig. 4

From: Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

Fig. 4

Scatterplot of Vilobelimab and C5a concentration (all available data, irrespective of visit). 9 value(s) from vilobelimab patients and 3 value(s) from placebo patients have been excluded from this figure due to incorrect timing or implausible values. Values below the lower limit of quantification are set to zero. Values above the upper limit of quantification are set to the upper limit of quantification. SOC Standard of care; Vilo  Vilobelimab

Back to article page